Caris Life Sciences, founded in 1996 and headquartered in Irving, Texas, has raised approximately $1.23 billion and achieved Unicorn status. The company leverages AI and machine learning through its DEAN analytics engine to deliver comprehensive tumor profiling and precision oncology solutions. Backed by investors such as T. Rowe Price and Silver Lake, Caris provides clinicians with molecular blueprints to guide personalized cancer treatment. Its mission is to advance precision medicine and improve patient outcomes through genomics-driven diagnostics and AI-powered clinical insights.